Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Tao Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5108-1774; OpenAlex author ID A5100455312. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers

Papers 8

  1. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.650264↗
  2. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.744667↗
  3. ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1. Co-author DOI 10.2139/ssrn.3439545↗
  4. Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. Last author DOI 10.2147/dddt.s156766↗
  5. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis. Co-author DOI 10.1007/s12032-016-0777-1↗
  6. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Co-author DOI 10.1038/aps.2015.4↗
  7. Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity. Co-author DOI 10.1007/s11427-014-4724-0↗
  8. Prognostic factors in patients with pancreatic cancer. Last author DOI 10.3892/etm.2011.412↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuanting Zheng · 3 shared papers, 2014–2016 · strength 0.17
  2. Weimin Cai · 3 shared papers, 2014–2016 · strength 0.17
  3. Zengyu Feng · 1 shared paper, 2021 · strength 0.15
  4. Kexian Li · 1 shared paper, 2021 · strength 0.15
  5. Chenghong Peng · 1 shared paper, 2021 · strength 0.15
  6. Yulian Wu · 1 shared paper, 2021 · strength 0.15
  7. Chun‐Bo Teng · 1 shared paper, 2018 · strength 0.14
  8. Jiamin Jin · 1 shared paper, 2018 · strength 0.14
  9. Zipeng Lu · 1 shared paper, 2021 · strength 0.13
  10. Rui Zhao · 1 shared paper, 2021 · strength 0.13
  11. Xiao Chen · 1 shared paper, 2021 · strength 0.13
  12. Kai Guo · 1 shared paper, 2021 · strength 0.13
  13. Yingying Cao · 1 shared paper, 2021 · strength 0.13
  14. Shuai Ren · 1 shared paper, 2021 · strength 0.13
  15. Zhongqiu Wang · 1 shared paper, 2021 · strength 0.13
  16. Tengfei Shao · 2 shared papers, 2014–2015 · strength 0.11
  17. Yang Zhou · 1 shared paper, 2019 · strength 0.10
  18. Rui Wang · 1 shared paper, 2019 · strength 0.10
  19. Yunjiang Zhou · 1 shared paper, 2019 · strength 0.10
  20. Rong Hu · 1 shared paper, 2019 · strength 0.10
  21. Jing Liu · 1 shared paper, 2016 · strength 0.07
  22. Dexiang Zhang · 1 shared paper, 2012 · strength 0.04
  23. Yuedi Dai · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.